Uncanny how you have a knack for these things Saul.
After the market closed this afternoon, Celgene Corporation (NASDAQ:CELG) announced that they have reached a settlement with Watson Laboratories, Inc., Natco Pharma Ltd. and Arrow International Limited regarding their recent REVLIMID patent litigation. As a part of the settlement, Celgene Corporation (NASDAQ:CELG) will allow for generic lenalidomide to enter the market prior to the April 2027 patent expiration, and has agreed to license their patents to Natco, which will allow them to sell generic lenalidomidein the U.S. starting in 2026, among other benefits. Shares of Celgene Corporation (NASDAQ:CELG) are trading up $8.86 or 7.97% in the after hours, following this news. The stock increased 0.27% or $0.3 during the last trading session, hitting $111.14. About 2.83 million shares traded hands. CELG has declined 5.14% since May 19, 2015 and is downtrending. It has underperformed the S&P500 by 2.88%.
http://ir.net/news/stock-news/122619/celgene-corporation-cel…